Back to Journals » Clinical and Experimental Gastroenterology » Volume 8

Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: a retrospective cohort study

Authors Matsumoto S, Yoshida Y

Received 13 April 2015

Accepted for publication 9 June 2015

Published 31 July 2015 Volume 2015:8 Pages 225—230

DOI https://doi.org/10.2147/CEG.S86528

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Andreas M Kaiser

Satohiro Matsumoto, Yukio Yoshida

Department of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Japan


Background: We conducted a retrospective cohort study to clinically and endoscopically assess the efficacy of delayed-release mesalazine for ulcerative colitis.
Methods: The study included 104 ulcerative colitis patients (52 men, 52 women) initiated on treatment with delayed-release mesalazine between 2009 and 2012. The clinical symptoms at months 0, 1, and 12 were scored using the clinical activity index. An endoscopic index was also used to determine disease activity in 72 patients who underwent total colonoscopy before and after mesalazine treatment.
Results: The clinical activity index at months 0, 1, and 12 were 4.6±2.8, 3.4±1.8, and 2.8±1.4, respectively, decreasing with time after the start of mesalazine treatment (P<0.001). The endoscopic index decreased significantly from 4.5±3.2 before to 3.1±2.8 after the start of delayed-release mesalazine treatment in the mean follow-up period of 1.0±0.4 years (P<0.001).
Conclusion: Delayed-release mesalazine was confirmed to be effective both clinically and endoscopically.

Keywords: ulcerative colitis, pH-dependent controlled-release mesalazine, clinical activity index, endoscopic index

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Pharmacologic therapy for inflammatory bowel disease refractory to steroids

Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G

Clinical and Experimental Gastroenterology 2015, 8:257-269

Published Date: 17 August 2015

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010